Bioqube Ventures, a European venture capital firm, and Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, entered a strategic collaboration for the development and manufacturing of biologics and small molecules.
 
The agreement aims to support the needs of the venture capital company (VC) and its portfolio companies looking to simplify the development of their molecules. Under the agreement, Lonza will support Bioqube Ventures during the due diligence of candidate biotechs and provide a tailored offering of advice and services to its portfolio companies.
 
The offering comprises Lonza’s expertise and technology for the development and manufacturing of molecules ranging from monoclonal antibodies, complex proteins, and small molecules to antibody-drug conjugates. The holistic approach to drug substance and drug product development and manufacturing across various platforms aims to significantly simplify the supply chain, reduce process complexity, and allow for a shortened development timelines.
 
Debora Dumont, Co-founder and Managing Partner, Bioqube Ventures, said, “Bioqube is dedicated to advancing exciting science in the vibrant European ecosystems with the aim of developing breakthrough therapies for patients. This collaboration offers our portfolio companies the opportunity to leverage Lonza’s expertise and its global network, supporting our hands-on approach in building new and successful ventures.”
 
Pnina Weitz, Global Head of Venture Capital Business Development & Relationship Management, Lonza, added: “This framework agreement provides Bioqube Ventures and its portfolio companies a range of services for its late discovery and early development needs. The cornerstone of our ability to successfully accelerate development programs and commercialize products is our proven track record, comprehensive resources and the global network that we bring to our customer’s portfolio companies. Our customized and scalable solutions demonstrate our commitment to enabling emerging biotechs to take their drug candidates to the clinic.